MedTrace Logo

Efficacy of 100% Trichloroacetic Acid Vs. Cryotherapy in Xanthelasma Palpebrarum

NCT06839638 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-21

No results posted yet for this study

Summary

Xanthelasma palpebrarum (XP) is a common skin condition characterized by yellowish plaques that typically develop around the eyelids. While not harmful, these plaques can be a cosmetic concern for many individuals. Several treatment options exist, but there is no clear consensus on the most effective method.

This study aims to compare the effectiveness of two treatment options-100% trichloroacetic acid (TCA) and cryotherapy-in removing xanthelasma palpebrarum. Trichloroacetic acid is a chemical solution that removes the lesions by controlled cauterization, while cryotherapy involves freezing the plaques using liquid nitrogen.

A total of 60 patients with xanthelasma will be randomly assigned to receive either 100% TCA or cryotherapy. The success of the treatment will be determined based on whether the plaques flatten and disappear within six weeks. The results of this study will help identify the more effective treatment method, which can be used to improve patient outcomes and minimize recurrence.

The study is being conducted at Nishtar Hospital Multan and aims to provide valuable insights for dermatologists in choosing the best treatment for xanthelasma palpebrarum.

Conditions

  • Xanthelasma Palpebrarum

Interventions

PROCEDURE

100% Trichloroacetic Acid (TCA)

Patients in this group will receive 100% TCA application to xanthelasma lesions using the dipstick method. The surrounding skin will be protected with white soft paraffin to prevent chemical spillage. Post-treatment, Fusidic acid 2% will be applied twice daily for one week. Treatment efficacy will be assessed after six weeks.

PROCEDURE

Cryotherapy (Liquid Nitrogen)

Patients in this group will receive cryotherapy using liquid nitrogen. A single freeze-thaw cycle will be performed until a narrow halo of white ice forms around the lesion. Post-treatment care will include Fusidic acid 2% applied twice daily for one week. Treatment efficacy will be assessed after six weeks.

Sponsors & Collaborators

  • Nishtar Medical University

    lead OTHER

Principal Investigators

  • Muhammad Irfan Jamil · Nishtar Hospital, Multan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-07
Primary Completion
2025-04-07
Completion
2025-04-07

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06839638 on ClinicalTrials.gov